ArticleIJTLD open2024
Updated treatment guidelines for drug-resistant TB: how safe are clofazimine-based regimens?
Article in IJTLD open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bedaquiline and linezolid regimens for multidrug-resistant tuberculosis: a systematic review and meta-analysis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025Pooled it
- A novel antituberculosis agent exhibits potent clinical efficacy and good safety profile: an open-label, randomized-controlled, multicenter, phase 2a trial.Signal transduction and targeted therapy · 2025Trial
- Management of adverse events in TB care and active TB drug safety monitoring.Breathe (Sheffield, England) · 2026Article
- A Comprehensive Review of Genetic Mechanisms ofInfection and drug resistance · 2026Review
- Article
- Article
- Genotypic and Phenotypic Methods in the Detection of MDR-TB and Evolution to XDR-TB.Antibiotics (Basel, Switzerland) · 2025Article
- 15-year trends in efficacy and effectiveness of treatment outcomes in drug-resistant pulmonary TB.IJTLD open · 2025Article
- Impact of new regimens and drugs on rifampin-resistant tuberculosis management in Mexico.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In June 2024, WHO released 'Key updates to the treatment of drug-resistant tuberculosis: rapid communication', after the preliminary publication of results from two clinical trials: 'BEAT-Tuberculosis' and 'endTB'. All proposed regimens include clofazimine (Cfz). However, a recent paper has reported a high incidence of QTc prolongation among patients receiving Cfz-based treatment for multidrug-resistant TB in Taiwan. Here, we discuss the cardiac safety of Cfz and the role of active drug safety monitoring at the programme level in collecting information on this issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.